Clinical trialNCT00164450CompletedInterventional

TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection

SponsorCenters for Disease Control and PreventionEnrollment158Tuberculosis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Compared to adults, children appear to require higher weight-based doses of rifapentine to acheive comparable drug levels. TBTC Study 26, a study of the effectiveness and tolerability of weekly rifapentine/isoniazid for three months versus daily isoniazid for nine months for the treatment of latent tuberculosis infection, has been amended to include children ages 2-11 based on an initial single-dose study and pharmacokinetic modeling. Study 26PK evaluates the adequacy of the doses chosen for young children enrolled in Study 26 with a single blood draw, 24 hours after the third or subsequent weekly Study 26 dose of rifapentine and isoniazid. An adult control is enrolled for each child enrolled.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Marc Weiner, MD
VAMC and University of Texas Health Science Center San Antonio
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Brazil

Hopital Universitario Clementino Fraga Filho
Rio de Janeiro, Brazil

Canada

University of British Columbia
Vancouver, British Columbia, Canada
University of Manitoba
Winnepeg, Manitoba, Canada
Montreal Chest Institute
Montreal, Quebec, Canada

Spain

Agencia de Salut Publica
Barcelona, Spain

United States

Central Arkansas Veterans Health System
Little Rock, Arkansas, United States
University of Southern California Medical Center
Los Angeles, California, United States
University of California at San Diego
San Diego, California, United States
University of California, San Francisco
San Francisco, California, United States
Denver Public Health Department
Denver, Colorado, United States
Washington Dc Veterans Administration Medical Center
Washington D.C., District of Columbia, United States
Emory University School of Medicine
Atlanta, Georgia, United States
Northwestern University School of Medicine
Chicago, Illinois, United States
Hines Veterans Administration Medical Center
Hines, Illinois, United States
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Boston University Medical Center
Boston, Massachusetts, United States
New Jersey School of Medicine
Newark, New Jersey, United States
Columbia University
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Veterans Administration Tennessee Valley Health Care System
Nashville, Tennessee, United States
University of North Texas Health Science Center
Fort Worth, Texas, United States
Houston Veterans Administration Medical Center
Houston, Texas, United States
Audie L. Murphy Va Hospital
San Antonio, Texas, United States
Seattle-King County Health Department
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Isoniazid →Rifapentine →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2005
Primary completion: 31 Aug 2008
Completion: 31 Aug 2008
Last update posted: 7 Jul 2026
Registered enrollment: 158
Registry id: NCT00164450

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.